Search

H-Net, the European Network for Harmonization of Training in Hematology, and its policy

H-Net, the 3-year European Network for Harmonization of Training in Hematology project led by Professor Eva Hellström-Lindberg, ended in September 2011, but its strongest components continue.

Read more

Welcome to the EHA2025 Sponsor Program

On this page, you can browse and/or download the interactive EHA2025 Sponsor Program. If the EHA2025 Sponsor Program does not display correctly, please click here or download the file.  

Read more

EHA Taskforce on Diversity, Equity, and Inclusion

The Diversity, Equity, and Inclusion Taskforce has a mandate from the EHA Board to develop a policy on Diversity, Equity, and Inclusion that will be the blueprint for:

Initiating and implementing activities to empower underrepresented groups.

Read more

Abstract submission & Awards

Abstract and Case Report submission is now closed. Abstract awardsIntroduced in 2021 and after 3 editions, we are excited to announce the 4th Emerging Investigators EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2024.

Read more

Press release: Work of 2013 Nobel Prize in Physiology or Medicine winners to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

With the Scientific Working Group for Stem Cells, the 18th Congress of EHA took the opportunity to acknowledge the work of the 2013 winner of the Nobel Prize for Medicine or Physiology, Drs John B.

Read more

EPICOVIDEHA survey

COVID-19 infections in patients with Hematological Malignancies - Results from EHA-IDWP registry
EPICOVIDEHA is an international open web-based registry for patients with haematological malignancies infected with SARS-CoV-2,
The survey has been approved by the Institutional Review Board and Ethics Committee of the…

Read more

EU Parliament agrees on pharmaceutical legislation stance

On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.

Read more